Rattlesnake Envenomations Treated Without Antivenom

Thumbnail
Name:
Chang P_Poster.pdf
Size:
502.0Kb
Format:
PDF
Description:
Poster
Download
Thumbnail
Name:
ChangP_thesis.pdf
Size:
231.8Kb
Format:
PDF
Description:
Thesis
Download
Author
Chang, Phoebe
Affiliation
The University of Arizona College of Medicine - Phoenix
Issue Date
2018-03-28
Keywords
Rattlesnake
Anti-Venoms
Envenomation
MeSH Subjects
Crotalus
Antivenins
Snake Bites

Metadata
Show full item record
Publisher
The University of Arizona.
Description
A Thesis submitted to The University of Arizona College of Medicine - Phoenix in partial fulfillment of the requirements for the Degree of Doctor of Medicine.
URI
http://hdl.handle.net/10150/627152
Abstract
The standard treatment for rattlesnake envenomation (RSE) is antivenom. The clinical course of patients treated with antivenom is well described. Prior to 2000, only a whole IgG AV (IgGAV) associated with high rates of hypersensitivity reactions (HSS) was available to treat RSE. Since 2000, Crotalidae Polyvalent Immune Fab (FabAV), which has a better safety profile than IgGAV, has been primarily used. Patients with RSE may not be treated with AV for a variety of reasons including history or perceived risk of HSS, patient refusal, drug shortage, or clinical impression that AV is not indicated. Research Question: What outcomes are associated with moderate to severe RSEs treated without antivenom?
Type
text; Electronic Thesis
Language
en_US
Collections